Search results for "Weight loss drugs"
AI and IM, updates on weight loss drugs, and more
This issue includes cover stories on AI and GLP-1s for weight loss, as well as a feature on a new career development program and a preview of Internal Medicine Meeting 2024, among other stories.
https://immattersacp.org/archives/2024/03/ai-and-im-updates-on-weight-loss-drugs-and-more.htm
1 Mar 2024
Studies look at weight loss, suicide risks for GLP-1s
A cohort study found significantly more weight loss in patients taking tirzepatide than semaglutide, while another analysis found no increased risk of suicide with glucagon-like peptide-1 (GLP-1) receptor agonists.
https://immattersacp.org/weekly/archives/2024/07/16/1.htm
16 Jul 2024
New 'weighs' to treat obesity
Even as the data on weight loss drugs mount, physicians need to help patients navigate potentially prohibitive costs and a continuing need for lifestyle change.
https://immattersacp.org/archives/2024/03/new-weighs-to-treat-obesity.htm
1 Mar 2024
Guideline suggests prescription medications when lifestyle change ineffective for weight loss
For adults with obesity or overweight with weight-related complications, the American Gastroenterological Association found moderate certainty of benefit for four medications: semaglutide, liraglutide, phentermine-topiramate ER, or naltrexone-bupropion.
https://immattersacp.org/weekly/archives/2022/10/25/1.htm
25 Oct 2022
What works well for weight loss
Nutrition and weight loss have become crucial issues to internists. Learn how one specialist manages her patients.
https://immattersacp.org/archives/2017/06/obesity.htm
1 Jun 2017
The next issue of ACP Internist is online and coming to your mailbox
The November issue of ACP Internist features stories about individualized treatment goals for diabetics, how to discuss dieting and weight management, and ways to diagnose skin and soft tissue infections.
https://immattersacp.org/weekly/archives/2012/11/06/8.htm
6 Nov 2012
NAFLD treatment starts with weight loss, then other modes
Nonalcoholic fatty liver disease (NAFLD), which accounts for 30% to 40% of chronic liver disease in the U.S. today, is the hepatic manifestation of the metabolic syndrome and is associated with sleep apnea, cardiovascular disease, and diabetes.
https://immattersacp.org/archives/2016/07/NAFLD.htm
1 Jul 2016